flecainide has been researched along with Cardiomyopathies, Primary in 12 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
| Excerpt | Relevance | Reference |
|---|---|---|
| "With flecainide, nine cases were reported at varying times after initiation of therapy, from in-hospital to 8 months." | 2.39 | Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. ( Prystowsky, EN, 1994) |
| "Fibrosis was triggered by transforming growth factor β (TGF-β) pathway activation." | 1.46 | Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease. ( Baró, I; Cerpa, CO; Charpentier, F; Colledge, WH; Derangeon, M; Girardeau, A; Grace, AA; Huang, CLH; Jagu, B; Montnach, J; Patin, J; Toumaniantz, G, 2017) |
| "Flecainide is a safe and effective antiarrhythmic medication, even for children with underlying CHD." | 1.46 | The Safety and Effectiveness of Flecainide in Children in the Current Era. ( Cunningham, T; Franciosi, S; Jeremiasen, I; Morris, R; Sanatani, S; Sherwin, E; Uzun, O; Wong, A, 2017) |
| "Flecainide was administered in 229 pts (6." | 1.42 | Flecainide use in children with cardiomyopathy or structural heart disease. ( delaUz, C; Kim, JJ; Krenek, M; Lupo, PJ; Miyake, C; Moffett, BS; Valdes, SO, 2015) |
| "Bidirectional ventricular tachycardia (BVT), although a rare arrhythmia in the general population, is frequently observed in patients with Andersen-Tawil syndrome and long QT interval." | 1.35 | Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome. ( Gonzalez, MD; Kalaizich, L; Pellizzón, OA; Ptácek, LJ; Tristani-Firouzi, M, 2008) |
| "Tachycardia was finally controlled with flecainide while the patient was on left ventricular assist device support." | 1.33 | Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy. ( Kaji, Y; Masuda, M; Morita, S; Nishida, T; Tatewaki, H; Ushinohama, H; Yasui, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ünal Yüksekgönül, A | 1 |
| Azak, E | 1 |
| Akalın, A | 1 |
| Ertuğrul, İ | 1 |
| Kılıç, E | 1 |
| Utine, GE | 1 |
| Karagöz, T | 1 |
| Derangeon, M | 1 |
| Montnach, J | 1 |
| Cerpa, CO | 1 |
| Jagu, B | 1 |
| Patin, J | 1 |
| Toumaniantz, G | 1 |
| Girardeau, A | 1 |
| Huang, CLH | 1 |
| Colledge, WH | 1 |
| Grace, AA | 1 |
| Baró, I | 1 |
| Charpentier, F | 1 |
| Cunningham, T | 1 |
| Uzun, O | 1 |
| Morris, R | 1 |
| Franciosi, S | 1 |
| Wong, A | 1 |
| Jeremiasen, I | 1 |
| Sherwin, E | 1 |
| Sanatani, S | 1 |
| Hyman, MC | 1 |
| Mustin, D | 1 |
| Supple, G | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Arkles, J | 1 |
| Lin, D | 1 |
| Muser, D | 1 |
| Dixit, S | 1 |
| Nazarian, S | 1 |
| Epstein, AE | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 1 |
| Frankel, DS | 1 |
| Capucci, A | 1 |
| Ciliberti, G | 1 |
| Guerra, F | 1 |
| Moffett, BS | 1 |
| Valdes, SO | 1 |
| Lupo, PJ | 1 |
| delaUz, C | 1 |
| Miyake, C | 1 |
| Krenek, M | 1 |
| Kim, JJ | 1 |
| Vallurupalli, S | 1 |
| Pothineni, NV | 1 |
| Deshmukh, A | 1 |
| Paydak, H | 1 |
| Calkins, H | 1 |
| Tatewaki, H | 1 |
| Masuda, M | 1 |
| Nishida, T | 1 |
| Kaji, Y | 1 |
| Ushinohama, H | 1 |
| Morita, S | 1 |
| Yasui, H | 1 |
| Pellizzón, OA | 1 |
| Kalaizich, L | 1 |
| Ptácek, LJ | 1 |
| Tristani-Firouzi, M | 1 |
| Gonzalez, MD | 1 |
| Prystowsky, EN | 1 |
| Villain, E | 1 |
| Bonnet, D | 1 |
| Kachaner, J | 1 |
| Le Bidois, J | 1 |
| Cohen, L | 1 |
| Piéchaud, JF | 1 |
| Sidi, D | 1 |
2 reviews available for flecainide and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
Topics: Ambulatory Care; Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Hospitalization; Humans; Prop | 1994 |
[Incessant idiopathic ventricular tachycardia in infants].
Topics: Amiodarone; Cardiomyopathies; Child, Preschool; Electrocardiography; Female; Flecainide; Follow-Up S | 1990 |
10 other studies available for flecainide and Cardiomyopathies, Primary
| Article | Year |
|---|---|
Efficacy of flecainide in bidirectional ventricular tachycardia and tachycardia-induced cardiomyopathy with Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Cardiomyopathies; Child; Female; Flecainide; Humans; Tachycardia; Tac | 2022 |
Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzamides; Cardiomyopathies; Co | 2017 |
The Safety and Effectiveness of Flecainide in Children in the Current Era.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Cohort Studies; Fe | 2017 |
Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Echocardiography; Electrocardiography; Female; Flecainide; | 2018 |
To the Editor- Flecainide and propafenone: Good twins for premature ventricular contractions' killing but not exactly superimposable.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Humans; Propafenone; Ventricular Premature Com | 2018 |
Flecainide use in children with cardiomyopathy or structural heart disease.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Child; Child, Preschool; Female; Flecainide; Heart Defects | 2015 |
Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone).
Topics: Arkansas; Cardiomyopathies; Echocardiography; Electrocardiography; Exercise Test; Female; Flecainide | 2015 |
Antiarrhythmic drug therapy in patients with arrhythmogenic dysplasia/cardiomyopathy: Is there a role for flecainide?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricular Dysplasia; Cardiomyop | 2017 |
Successful treatment of tachycardia-induced cardiomyopathy with LVAD in a 12-year-old boy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Child; Flecainide; Heart Failure; Heart-Assist Devices; Hu | 2005 |
Flecainide suppresses bidirectional ventricular tachycardia and reverses tachycardia-induced cardiomyopathy in Andersen-Tawil syndrome.
Topics: Adolescent; Andersen Syndrome; Anti-Arrhythmia Agents; Cardiomyopathies; Female; Flecainide; Humans; | 2008 |